Evaluation of Selected Natural Compounds as Dual Inhibitors of Catechol-O-Methyltransferase and Monoamine Oxidase
Open Access
- 6 August 2019
- journal article
- Published by Bentham Science Publishers Ltd. in Central Nervous System Agents in Medicinal Chemistry
- Vol. 19 (2) , 133-145
Abstract
Background: The most effective symptomatic treatment of Parkinson’s disease remains the metabolic precursor of dopamine, L-dopa. To enhance the efficacy of L-dopa, it is often combined with inhibitors of the enzymes, catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO) B, key metabolic enzymes of L-dopa and dopamine. Objective: This study attempted to discover compounds that exhibit dual inhibition of COMT and MAO-B among a library of 40 structurally diverse natural compounds. Such dual acting inhibitors may be effective as adjuncts to L-dopa and offer enhanced value in the management of Parkinson’s disease. Methods: Selected natural compounds were evaluated as in vitro inhibitors of rat liver COMT and recombinant human MAO. Reversibility of MAO inhibition was investigated by dialysis. Results: Among the natural compounds morin (IC50 = 1.32 µM), chlorogenic acid (IC50 = 6.17 µM), (+)-catechin (IC50 = 0.86 µM), alizarin (IC50 = 0.88 µM), fisetin (IC50 = 5.78 µM) and rutin (IC50 = 25.3 µM) exhibited COMT inhibition. Among these active COMT inhibitors only morin (IC50 = 16.2 µM), alizarin (IC50 = 8.16 µM) and fisetin (IC50 = 7.33 µM) were noteworthy MAO inhibitors, with specificity for MAO-A. Conclusion: None of the natural products investigated here are dual COMT/MAO-B inhibitors. However, good potency COMT inhibitors have been identified, which may serve as leads for future development of COMT inhibitors.Keywords
Funding Information
- National Research Foundation, NRF ((UID) 105770, 105834)
This publication has 54 references indexed in Scilit:
- Levodopa: A new look at an old friendMovement Disorders, 2017
- Glutathione metabolism and Parkinson's diseaseFree Radical Biology and Medicine, 2013
- Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illnessBritish Journal of Pharmacology, 2006
- Alternatives to Levodopa in the Initial??Treatment of Early Parkinson???s DiseaseDrugs & Aging, 2005
- Autoxidation and MAO-mediated metabolism of dopamine as a potential cause of oxidative stress: role of ferrous and ferric ionsNeurochemistry International, 2004
- Parkinson's DiseaseNeuron, 2003
- Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's diseaseProgress in Neurobiology, 2001
- History of levodopa and dopamine agonists in Parkinson's disease treatmentNeurology, 1998
- Dopamine Oxidation Generates an Oxidative Stress Mediated by Dopamine Semiquinone and Unrelated to Reactive Oxygen SpeciesJournal of Molecular and Cellular Cardiology, 1997
- An endogenous dopaminergic neurotoxin: Implication for Parkinson's diseaseNeurodegeneration, 1995